Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II G-ICE with MRD/PET-guided ASCT strategy in relapsed/refractory diffuse large B-cell lymphoma
KCT0011836Phase 2Recruiting
- Sponsor
- Roche
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab, ifosfamide, carboplatin, etoposide and obinutuzumab in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Roche. Primary endpoint: Complete response rate after completion of treatment. Started Aug 2026; status: recruiting.
02
Drugs
glofitamabifosfamidecarboplatinetoposideobinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0011836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011836.